NASDAQ$SIBN
SI-BONE Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
SI-BONE Inc reported $48.6 million in revenue for the second quarter of 2025, up 22% year over year.
SI-BONE Inc delivered revenue of $48.6 million in Q2 2025, reflecting 22% growth driven by higher U.S. case volumes and an expanded product portfolio. The company narrowed its net loss to $6.2 million from $8.9 million in the prior-year quarter while maintaining a gross margin of 79.8%. Cash and cash equivalents stood at $34.2 million with total assets of $230.9 million at quarter end.
- Q2 revenue reached $48.6 million, a 21.7% increase from $40.0 million in Q2 2024, led by U.S. sales growth of 22.8%.
- Gross margin improved to 79.8% from 79.0% due to favorable product mix and lower unit costs.
- Net loss narrowed to $6.2 million ($0.14 per share) from $8.9 million ($0.22 per share) year over year.
- U.S. revenue accounted for 95.5% of total revenue while international revenue grew modestly to $2.2 million.
Headline financials
Revenue & EPS history
SI-BONE · Revenue · Quarterly
$48.6M
Forward guidance
The company continues to focus on expanding its sacropelvic solutions portfolio and physician engagement while monitoring macroeconomic factors including tariffs and supply chain dynamics.
Tailwinds
- Strong revenue growth driven by new product adoption
- Improved gross margins from product mix and cost efficiencies
Headwinds
- Ongoing net losses and cash usage from operations
- Potential impact from tariffs on international sales and supply chain costs
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
-1.8%
Avg return
Earnings day
-1.3%
Avg return
5 days after
+0.0%
Avg return
30 days after
40%
12 / 30 earnings
Positive
+16.2%
Q4 2022
Best reaction
-23.7%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -5.3% | +15.3% | +25.1% | |
| Q4 2025 | -1.0% | -0.6% | -17.8% | |
| Q3 2025 | +16.1% | +11.1% | +20.0% | |
| Q1 2025 | +15.6% | +29.8% | +33.8% | |
| Q4 2024 | +5.6% | +3.7% | -19.9% | |
| Q3 2024 | -17.5% | -18.8% | -14.5% | |
| Q2 2024 | -3.6% | -5.2% | +10.2% | |
| Q1 2024 | +10.4% | +8.0% | -1.1% | |
| Q4 2023 | -12.4% | -15.7% | -22.0% | |
| Q3 2023 | -4.7% | -12.4% | -0.9% | |
| Q2 2023 | -12.5% | -9.6% | -7.1% | |
| Q1 2023 | +9.6% | -0.3% | +13.9% | |
| Q4 2022 | +16.2% | +19.5% | +14.0% | |
| Q3 2022 | -23.1% | -16.4% | -26.5% | |
| Q2 2022 | -6.4% | +0.1% | +3.5% | |
| Q1 2022 | -23.7% | -27.6% | -12.2% | |
| Q4 2021 | +2.4% | +3.2% | +3.2% | |
| Q3 2021 | -7.8% | -10.9% | -13.6% | |
| Q2 2021 | -15.1% | -18.9% | -18.3% | |
| Q1 2021 | -7.0% | -7.5% | -17.2% | |
| Q4 2020 | +4.0% | +6.6% | +8.3% | |
| Q3 2020 | +3.2% | +0.5% | +10.7% | |
| Q2 2020 | +13.6% | +17.7% | +31.7% | |
| Q1 2020 | +9.0% | +11.9% | +16.3% | |
| Q4 2019 | -11.9% | -21.7% | -28.9% | |
| Q3 2019 | -4.4% | -4.5% | -0.6% | |
| Q2 2019 | +6.8% | +10.7% | +11.3% | |
| Q1 2019 | -3.9% | -8.1% | -1.5% | |
| Q4 2018 | -4.6% | -3.6% | -9.4% | |
| Q3 2018 | -3.0% | +4.8% | +10.5% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro